Activation of PKA leads to mesenchymal-to-epithelial transition and loss of tumor-initiating ability

Abstract
The epithelial-to-mesenchymal transition enables carcinoma cells to acquire malignancy-associated traits and the properties of tumor-initiating cells (TICs). TICs have emerged in recent years as important targets for cancer therapy, owing to their ability to drive clinical relapse and enable metastasis. Here, we propose a strategy to eliminate mesenchymal TICs by inducing their conversion to more epithelial counterparts that have lost tumor-initiating ability. We report that increases in intracellular levels of the second messenger, adenosine 3′,5′-monophosphate, and the subsequent activation of protein kinase A (PKA) induce a mesenchymal-to-epithelial transition (MET) in mesenchymal human mammary epithelial cells. PKA activation triggers epigenetic reprogramming of TICs by the histone demethylase PHF2, which promotes their differentiation and loss of tumor-initiating ability. This study provides proof-of-principle for inducing an MET as differentiation therapy for TICs and uncovers a role for PKA in enforcing and maintaining the epithelial state.
Funding Information
  • National Health and Medical Research Council of Australia (NHMRC APP1071853)
  • National Research Foundation, Singapore (NRF-NRFF2015-04)
  • National Medical Research Council, Singapore (NMRC/TCR/007-NCC/2013)
  • Ludwig Center for Molecular Oncology at MIT
  • Breast Cancer Research Foundation
  • Samuel Waxman Cancer Research Foundation
  • NIH (R01-CA078461)
  • American Cancer Society
  • D. K. Ludwig Foundation Cancer Research